Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

319.50USD
2:18am IST
Change (% chg)

$0.29 (+0.09%)
Prev Close
$319.21
Open
$318.96
Day's High
$323.30
Day's Low
$313.42
Volume
288,414
Avg. Vol
547,205
52-wk High
$388.67
52-wk Low
$249.24

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 21.50 31.23 33.59
EPS (TTM): 15.23 -- --
ROI: 17.59 15.57 15.05
ROE: 28.64 16.94 16.62

Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

25 Oct 2018

UPDATE 2-Eisai, Biogen Alzheimer's data fails to convince skeptics

Oct 25 Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

25 Oct 2018

UPDATE 1-Biogen shares slip after Alzheimer's data fails to convince

Oct 25 Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.

25 Oct 2018

Biogen/Eisai Alzheimer's data suggests treatment effect related to drug

Oct 25 Biogen and partner Eisai Co Ltd said data from their experimental Alzheimer's drug suggested that the treatment effect for the highest dose was related to the drug, and not to an imbalance of patients in the treatment groups.

25 Oct 2018

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

24 Oct 2018

UPDATE 1-Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

Oct 24 A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

24 Oct 2018

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

Oct 24 A U.S. appeals court on Wednesday upheld a ruling that patents owned by Biogen Inc covering its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

24 Oct 2018

Biogen's Spinraza drives third-quarter profit beat

Biogen Inc on Tuesday handily beat Wall Street expectations for third quarter profit, led by strong demand for its new blockbuster muscle disease treatment Spinraza.

23 Oct 2018

UPDATE 3-Biogen's Spinraza drives third-quarter profit beat

* MS drug Tecfidera misses analyst estimates (Adds CEO, analyst comment, share movement, Spinraza details from conference call)

23 Oct 2018

Biogen third-quarter profit rises 17.8 pct

Oct 23 Biogen Inc reported a 17.8 percent rise in third-quarter profit on Tuesday, driven by double-digit sales growth of its promising muscle disease treatment Spinraza.

23 Oct 2018

Earnings vs. Estimates